Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission
- 19 November 2018
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 94 (2), 231-239
- https://doi.org/10.1002/ajh.25355
Abstract
Acute myeloid leukemia (AML) in first remission (CR1) with isolated NPM1 mutation (iNPM1m) is considered a good prognosis genotype, although up to one third relapse. To evaluate the best transplant strategy, we retrospectively compared autologous stem cell transplantation (auto‐SCT), related (MSD) and fully matched unrelated (MUD) allogeneic stem cell transplantation (allo‐SCT). We identified 256 adult patients including 125 auto‐SCT, 72 MSD and 59 MUD. The 2‐year leukemia‐free survival (LFS) was 62% in auto‐SCT, 69% in MUD and 81% in MSD (p=0.02 for MSD versus others). The 2‐year overall survival (OS) was not different among auto‐SCT, MUD and MSD, reaching 83% (p=0.88). The 2‐year non‐relapse mortality (NRM) was 2.5% in auto‐SCT and 7.5% in allo‐SCT (p=0.04). The 2‐year cumulative incidence of relapse (RI) was higher after auto‐SCT (30%) than after MUD (22%) and MSD (12%, p=0.01). In multivariate analysis, MSD versus auto‐SCT but not MUD versus auto‐SCT was associated with lower RI (pNPM1m AML in CR1. Auto‐SCT was followed by worse RI and LFS, but similar OS to both allo‐SCT modalities.This publication has 46 references indexed in Scilit:
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2016
- Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trialsBlood, 2010
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete RemissionJAMA, 2009
- Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomesBlood, 2009
- Identical Outcome After Autologous or Allogeneic Genoidentical Hematopoietic Stem-Cell Transplantation in First Remission of Acute Myelocytic Leukemia Carrying Inversion 16 or t(8;21): A Retrospective Study From the European Cooperative Group for Blood and Marrow TransplantationJournal of Clinical Oncology, 2008
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid LeukemiaThe New England Journal of Medicine, 2008
- Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?Blood, 2007
- Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal KaryotypeThe New England Journal of Medicine, 2005
- Prognostically Useful Gene-Expression Profiles in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2004